Core Viewpoint - GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2026, GT Biopharma is expected to earn -$0.32 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 54.3% over the past three months, reflecting a positive trend in earnings outlook [8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of GT Biopharma to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Viewpoint - GT Biopharma, Inc. (GTBP) has experienced a decline of 6.6% in its stock price over the past four weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out of the stock, with reduced selling pressure and a potential shift in control from bears to bulls [2][5]. - This pattern is characterized by a small candle body with a long lower wick, signifying that despite a new low being reached, buying interest has emerged to push the stock price up towards its opening price [4][5]. Fundamental Analysis - There has been a significant upward trend in earnings estimate revisions for GTBP, with a 54.3% increase in the consensus EPS estimate for the current year over the last 30 days, indicating strong agreement among analysts that the company will report better earnings than previously predicted [7][8]. - GTBP holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically correlates with outperformance in the market [9][10].

Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE NK cell engager platform [1][3] - Michael Breen, the Executive Chairman and CEO, will participate in the 38th Annual Roth Conference from March 22-24, 2026 [1][2] Company Overview - GT Biopharma specializes in the development and commercialization of immuno-oncology therapeutic products utilizing the TriKE NK cell engager platform, which enhances the cancer-killing abilities of natural killer cells [3] - The company holds an exclusive worldwide license agreement with the University of Minnesota for the further development and commercialization of therapies using TriKE technology [3]

Financial Performance - Net loss increased by approximately $15.2 million to $(28,354,000) for the year ended December 31, 2025, representing a 115% increase compared to the prior year[230] - Total operating expenses decreased by $1,942,000 to $12,422,000 for the year ended December 31, 2025, reflecting a 14% decline[219] - Selling, general, and administrative expenses increased slightly by $182,000 to $8,518,000 for the year ended December 31, 2025, a 2% increase[222] Cash Flow - Net cash used in operating activities was approximately $12.9 million for the year ended December 31, 2025, primarily due to a net loss and a decrease in accounts payable and accrued expenses[235] - Net cash provided by financing activities was approximately $15.8 million for the year ended December 31, 2025, resulting from net proceeds from the issuance of Series L Preferred Stock and warrants[238] - Cash and cash equivalents and restricted cash increased to $6,905,000 at the end of the period, up from $4,044,000 at the beginning of the period[234] Assets and Liabilities - Current assets increased to $8,106,000 in 2025 from $4,232,000 in 2024, representing a growth of 91.8%[239] - Current liabilities decreased to $2,319,000 in 2025 from $5,902,000 in 2024, a reduction of 60.7%[239] - Working capital improved significantly to $5,787,000 in 2025 from a deficit of $1,670,000 in 2024, an increase of $7,457,000[239] Research and Development - Research and development expenses decreased by approximately $2.3 million to $3,472,000 for the year ended December 31, 2025, a 40% reduction compared to the prior year[219] Market and Risk Assessment - The company has raised substantial doubt about its ability to continue as a going concern, with expectations of continued operating losses[231] - The company qualifies as a smaller reporting company and is not required to provide additional market risk information[241] Other Financial Metrics - Interest income decreased by $279,000 to $123,000 for the year ended December 31, 2025, primarily due to lower investment balances[224] - The change in fair value of warrant liability decreased by $559,000 to $241,000 for the year ended December 31, 2025, due to a decline in the company's stock price[226] - The company has no off-balance sheet arrangements as of December 31, 2025[240]

Core Insights - The company is advancing its clinical pipeline with significant milestones expected in 2026, including the initiation of the first clinical trial for GTB-5550 [2] - GTB-3650 has demonstrated a favorable safety profile, and higher dose cohorts are anticipated to provide insights into efficacy [2] - The company has sufficient cash runway, projected to last through Q4 2026, with an unaudited proforma cash balance of approximately $9 million as of January 31, 2026 [6] Clinical Trials - The Phase 1 trial for GTB-3650 is ongoing, focusing on relapsed or refractory CD33 expressing hematologic malignancies, with enrollment in Cohort 4 continuing and dosing in Cohort 5 expected to start in Q2 2026 [3] - The Phase 1 basket trial for GTB-5550 is set to begin in mid-2026, testing multiple solid tumor types that express B7-H3, with a focus on identifying the maximum tolerated dose [4][8] - GTB-5550 will be administered via subcutaneous injection, with treatment cycles lasting four weeks and patient assessments occurring every 8-12 weeks [5] Financial Performance - The company reported cash and cash equivalents of approximately $7 million as of December 31, 2025, with a decrease in R&D expenses to approximately $3.5 million from $5.8 million the previous year [6][7] - Selling, General and Administrative (SG&A) expenses remained relatively stable at approximately $8.5 million compared to $8.3 million in the prior year [9] - The company reported a net loss of approximately $28.4 million for the year ended December 31, 2025, an increase from $13.2 million the previous year, primarily due to a non-cash expense related to investment rights [11]

Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE NK cell engager platform [1][3] - The company will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on March 5, 2026, where one-on-one meetings with investors will be available [1][2] Company Overview - GT Biopharma is dedicated to the development and commercialization of immuno-oncology therapeutic products utilizing the TriKE platform, which enhances the cancer-killing abilities of natural killer cells in the immune system [3] - The company holds an exclusive worldwide license agreement with the University of Minnesota for the further development and commercialization of therapies using TriKE technology [3]

Core Insights - GT Biopharma has received FDA clearance for its IND application for GTB-5550, allowing the initiation of a Phase 1 clinical trial expected to start in mid-2026 [1][2] - The Phase 1 trial will focus on multiple solid tumor types expressing B7-H3, with a priority on advanced prostate, ovarian, and pancreatic cancer patients who have failed standard therapies [2][3] - The company anticipates an unaudited proforma cash balance of approximately $9 million as of January 31, 2026, which is expected to extend its cash runway through Q4 2026 [1] Company Overview - GT Biopharma is a clinical stage immuno-oncology company that develops therapeutics based on its proprietary TriKE NK cell engager platform [5] - The TriKE platform aims to enhance the cancer-killing abilities of natural killer cells in the immune system [5] - The company has an exclusive worldwide license agreement with the University of Minnesota for the development and commercialization of therapies using TriKE technology [5] Clinical Trial Details - The Phase 1 trial will include a dose escalation component testing up to 6 dose levels to identify the maximum tolerated dose (MTD) [3] - Following the dose escalation, a Phase 1b expansion will confirm the MTD in various metastatic disease cohorts, including castration-resistant prostate cancer and others [3] - GTB-5550 will be administered via subcutaneous injection for 5 consecutive days during the first two weeks of each 4-week treatment cycle, with patient follow-up for 12 months to assess progression-free survival and overall survival [4]

As filed with the Securities and Exchange Commission on January 21, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GT BIOPHARMA, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 2834 94-1620407 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) N/A (415) 919-4040 ( ...

Core Insights - GT Biopharma is targeting a segment of the estimated $362 billion global solid tumor market with its investigational drug GTB-5550, a B7-H3-targeted NK cell engager [1][2] - The company has submitted an IND application to the FDA for GTB-5550, which is expected to enter clinical trials in 2026 [1][2] - The company anticipates a cash balance of approximately $7 million as of December 31, 2025, which is expected to extend its cash runway into Q3 2026 [1] Company Overview - GT Biopharma is a clinical stage biopharmaceutical company focused on developing immuno-oncology therapeutics based on its proprietary TriKE NK cell engager platform [6] - The company has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology [6] Product Development - GTB-5550 is a tri-specific NK cell engager designed to enhance the cancer-killing abilities of NK cells by targeting B7-H3 expressed on tumor cells [3] - The planned Phase 1 trial for GTB-5550 will be the first dual nanobody TriKE tested with subcutaneous dosing, aiming to identify the maximum tolerated dose (MTD) across various metastatic cancers [4] - The trial will include a dose escalation phase and a dose expansion phase, evaluating tolerability and efficacy in multiple solid tumor cohorts [4][5] Market Potential - The global market for B7-H3 expressing solid tumor cancers is a significant portion of the overall solid tumor market, indicating a large potential patient population for GTB-5550 [2]

Core Viewpoint - GT Biopharma Inc. has submitted an investigational new drug (IND) application for GTB-5550 TriKE, targeting B7-H3-expressing solid tumors, marking a significant step in its clinical development pipeline [1][2]. Company Developments - The IND for GTB-5550 is the third NK cell engager the company plans to advance into clinical trials, with a Phase 1 basket trial scheduled for 2026 [2]. - The company is currently enrolling patients in a Phase 1 trial for GTB-3650, focusing on myeloid blood cancer, with data readout expected in the first half of 2026 [3]. Market Context - The global market for B7-H3 expressing solid tumor cancers is part of the estimated $362 billion global solid tumor cancers market, indicating substantial commercial potential [3]. Trial Design - The Phase 1a trial will include a dose escalation study to determine the maximum tolerated dose (MTD) across 7 dose levels [4]. - The Phase 1b trial will confirm the MTD identified in Phase 1a and evaluate tolerability across distinct metastatic disease cohorts [4]. Treatment Protocol - GTB-5550 will be administered via subcutaneous injection for 5 consecutive days during the first two weeks, followed by a treatment-free period, with a minimum of 2 treatment cycles planned [5]. - Patients will be monitored for 12 months to assess progression-free survival (PFS) and overall survival (OS) [6]. Stock Performance - Following the announcement, GTBP stock experienced a 12.92% increase, reaching $0.75 in premarket trading [6].